Proscia, a provider of digital and computational pathology solutions, has announced that Laboratorium Pathologie Oost-Nederland (LabPON), the first laboratory in the world to 100% digital pathology diagnosis, will deploy its Concentriq platform.
In transitioning to Concentriq, LabPON gains added flexibility to scale its routine digital pathology operations as the total number of worldwide cancer cases continues to rise. This includes establishing the software infrastructure for later implementing computational applications using artificial intelligence (AI) to improve diagnostic quality and efficiency.
Laboratories are increasingly shifting to digital pathology to overcome the manual and subjective nature of today’s microscope-based standard of care, and, more recently, to maintain operations in the face of COVID-19. As a part of this digital transformation, they are implementing a complex ecosystem of hardware and software solutions to address the end-to-end pathology workflow.
LabPON, one of the earliest adopters of digital pathology in clinical practice, has recognised the need for a secure, enterprise-class platform with best-of-breed interoperability to centralise its routine pathology operations and address its current and future requirements. It has chosen Proscia’s CE/IVD-certified Concentriq Dx platform to serve as the foundation for expanding its practice with the freedom to choose the best components of an integrated digital pathology ecosystem.
“Proscia’s Concentriq will grow with our laboratory by enabling us to rapidly deploy innovative solutions to meet the ever-evolving needs of our team,” said LabPON director Rycolt Hamoen. “We rigorously evaluated multiple enterprise imaging platforms and chose Concentriq because it gives us full flexibility and infinite scalability with its truly open approach,” added Pieter van der Vorm (pictured), lead pathologist for the evaluation of novel technologies at LabPON.
Designed to enable AI applications, Concentriq provides LabPON with the software infrastructure to realise the promise of pathology’s computational future. In the first phase of its journey, LabPON will use the platform to validate the efficacy of Proscia’s AI applications and generate clinical and economic evidence on their ability to achieve their intended purposes. LabPON will also collaborate with Proscia on the development of computational applications by creating de-identified datasets to be used in training algorithms. It can then deploy these applications, along with other third-party solutions, on Concentriq to expand the breadth of diagnostic information available to its team.